{"filing":{"accession_number":"0001193125-26-286829","cik":"0001937653","ticker":"ZYME","company_name":"Zymeworks Inc.","form":"8-K","filing_date":"2026-06-29","report_date":null,"primary_document":"d156494d8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1937653/000119312526286829/d156494d8k.htm"},"events":[{"id":14459,"run_id":12872,"accession_number":"0001193125-26-286829","anchor_item_number":"1.01","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.99,"summary":"Zymeworks entered into a definitive Agreement and Plan of Merger on June 28, 2026, to acquire Theravance Biopharma for $17.00 per share (approximately $929 million in total cash consideration), including contingent value rights tied to future product monetization. The transaction adds YUPELRI® and associated royalty streams to Zymeworks' portfolio.","company_name":"Zymeworks Inc.","ticker":"ZYME","filing_date":"2026-06-29","form":"8-K","submitted_at":null,"items":[{"id":11904,"accession_number":"0001193125-26-286829","item_number":"1.01","item_title":"Entry into a Material Definitive Agreement","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.99,"reasoning":"Zymeworks entered into a definitive Agreement and Plan of Merger on June 28, 2026, to acquire Theravance Biopharma for $17.00 per share (approximately $929 million in total cash consideration). The transaction involves a merger structure with contingent value rights tied to future product monetization. This is a material acquisition that would significantly affect investor assessment of Zymeworks' strategic direction, cash flows, and asset portfolio, particularly the addition of YUPELRI® and associated royalty streams.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-29T11:21:40.353800+00:00","company_name":"","ticker":null,"filing_date":""},{"id":11905,"accession_number":"0001193125-26-286829","item_number":"7.01","item_title":"Regulation FD Disclosure","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.98,"reasoning":"Zymeworks announced entry into a definitive merger agreement to acquire Theravance Biopharma for $17.00 per share (~$929 million total consideration). The press release explicitly states \"Zymeworks Inc. (Nasdaq: ZYME)...today announced it has entered into a definitive agreement to acquire Theravance Biopharma, Inc.\" This is a material acquisition of a biopharmaceutical company with established commercial products (YUPELRI®) and royalty streams, representing a significant strategic transaction that would materially affect investor assessment of the registrant's business, cash flows, and capital allocation.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-29T11:21:40.353800+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":11904,"accession_number":"0001193125-26-286829","item_number":"1.01","item_title":"Entry into a Material Definitive Agreement","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.99,"reasoning":"Zymeworks entered into a definitive Agreement and Plan of Merger on June 28, 2026, to acquire Theravance Biopharma for $17.00 per share (approximately $929 million in total cash consideration). The transaction involves a merger structure with contingent value rights tied to future product monetization. This is a material acquisition that would significantly affect investor assessment of Zymeworks' strategic direction, cash flows, and asset portfolio, particularly the addition of YUPELRI® and associated royalty streams.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-29T11:21:40.353800+00:00","company_name":"Zymeworks Inc.","ticker":"ZYME","filing_date":"2026-06-29"},{"id":11905,"accession_number":"0001193125-26-286829","item_number":"7.01","item_title":"Regulation FD Disclosure","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.98,"reasoning":"Zymeworks announced entry into a definitive merger agreement to acquire Theravance Biopharma for $17.00 per share (~$929 million total consideration). The press release explicitly states \"Zymeworks Inc. (Nasdaq: ZYME)...today announced it has entered into a definitive agreement to acquire Theravance Biopharma, Inc.\" This is a material acquisition of a biopharmaceutical company with established commercial products (YUPELRI®) and royalty streams, representing a significant strategic transaction that would materially affect investor assessment of the registrant's business, cash flows, and capital allocation.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-29T11:21:40.353800+00:00","company_name":"Zymeworks Inc.","ticker":"ZYME","filing_date":"2026-06-29"}]}